Literature DB >> 26622333

siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells.

Xiao-Yan Gao1, Ye-Han Zhu2, Li-Xin Zhang3, Hui-Yu Lu1, Ai-Gui Jiang1.   

Abstract

The aim of the present study was to investigate the effect of the small interfering RNA (siRNA)-induced inhibition of the Trop2 gene on the proliferation and invasion of lung adenocarcinoma H460 cells. A recombinant adenovirus expression vector, which contained siRNA targeting open reading frames for Trop2 (rAd5-siTrop2), was transfected into lung adenocarcinoma H460 cells. Three groups were included in the study, namely the Ctrl (non-transfected control), rAd5-siCtrl (native control) and rAd5-siTrop2 (knockdown Trop2 gene) groups. The mRNA and protein expression levels of Trop2 were detected using quantitative polymerase chain reaction and western blot analysis, respectively. In addition, the expression levels of cyclin Dl and phospho-extracellular signal regulated kinase (p-ERK)-1 were detected using western blot analysis. The effects of Trop2 inhibition on the proliferation and invasion of lung adenocarcinoma H460 cells were investigated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Transwell assay. Trop2-targeted siRNA recombinant plasmids were successfully constructed. The recombinant adenovirus vector, rAd5-siTrop2, significantly downregulated the mRNA and protein expression levels of Trop2 in the lung adenocarcinoma H460 cells, with cyclin D1 and p-ERK-1 expression downregulated simultaneously. In addition, following the silencing of Trop2, the proliferation and invasion rates of the lung adenocarcinoma H460 cells were reduced. Therefore, the results indicated that Trop2 serves a key function in the proliferation and invasion of lung adenocarcinoma H460 cells in vitro.

Entities:  

Keywords:  Trop2; lung adenocarcinoma; small interfering RNA

Year:  2015        PMID: 26622333      PMCID: PMC4509052          DOI: 10.3892/etm.2015.2530

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  21 in total

1.  Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization.

Authors:  G Calabrese; C Crescenzi; E Morizio; G Palka; E Guerra; S Alberti
Journal:  Cytogenet Cell Genet       Date:  2001

2.  Short hairpin RNA targeting AKT1 and PI3K/p85 suppresses the proliferation and self-renewal of lung cancer stem cells.

Authors:  Ai-Gui Jiang; Hui-Yu Lu; De-Geng Zhang; Li-Xin Zhang; Xiao-Yan Gao
Journal:  Mol Med Rep       Date:  2015-02-26       Impact factor: 2.952

3.  Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.

Authors:  Christopher J Nelsen; Ryoko Kuriyama; Betsy Hirsch; Vivian C Negron; Wilma L Lingle; Melissa M Goggin; Michael W Stanley; Jeffrey H Albrecht
Journal:  J Biol Chem       Date:  2004-10-26       Impact factor: 5.157

4.  Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.

Authors:  Chizuko Yamamoto; Yuji Basaki; Akihiko Kawahara; Kazutaka Nakashima; Masayoshi Kage; Hiroto Izumi; Kimitoshi Kohno; Hidetaka Uramoto; Kosei Yasumoto; Michihiko Kuwano; Mayumi Ono
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

Review 5.  The other side of MMPs: protective roles in tumor progression.

Authors:  Michelle D Martin; Lynn M Matrisian
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

6.  Significance of 14-3-3 self-dimerization for phosphorylation-dependent target binding.

Authors:  Ying H Shen; Jakub Godlewski; Agnieszka Bronisz; Jun Zhu; Michael J Comb; Joseph Avruch; Guri Tzivion
Journal:  Mol Biol Cell       Date:  2003-08-07       Impact factor: 4.138

7.  EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Angela Unholzer; Gudrun Amann; Michaela Kronawitter; Ingo Bauerfeind; Andrea Sendelhofert; Anette Iff; Udo Löhrs
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

8.  Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.

Authors:  Rafael Cubas; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer       Date:  2010-09-21       Impact factor: 27.401

9.  Significance of EpCAM and TROP2 expression in non-small cell lung cancer.

Authors:  Min Gyoung Pak; Dong Hoon Shin; Chang Hun Lee; Min Ki Lee
Journal:  World J Surg Oncol       Date:  2012-04-06       Impact factor: 2.754

10.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

Authors:  D Fong; P Moser; C Krammel; J M Gostner; R Margreiter; M Mitterer; G Gastl; G Spizzo
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  2 in total

Review 1.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.

Authors:  David M Goldenberg; Rhona Stein; Robert M Sharkey
Journal:  Oncotarget       Date:  2018-06-22

2.  Silencing of the TROP2 gene suppresses proliferation and invasion of hepatocellular carcinoma HepG2 cells.

Authors:  Jian Zhang; Hai Ma; Liu Yang; Hongchun Yang; Zhenxing He
Journal:  J Int Med Res       Date:  2019-01-24       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.